These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9387520)

  • 1. [Research on molecular genetics in gynecologic tumor: development and regulation].
    Wang Y
    Zhonghua Fu Chan Ke Za Zhi; 1996 Nov; 31(11):643-5. PubMed ID: 9387520
    [No Abstract]   [Full Text] [Related]  

  • 2. [Gynecologic malignancies].
    Sagae S; Koizumi M; Terasawa K; Kobayashi K; Kudo R
    Tanpakushitsu Kakusan Koso; 1997 Jul; 42(10 Suppl):1762-70. PubMed ID: 9279110
    [No Abstract]   [Full Text] [Related]  

  • 3. Biallelic methylation and silencing of paternally expressed gene 3 (PEG3) in gynecologic cancer cell lines.
    Dowdy SC; Gostout BS; Shridhar V; Wu X; Smith DI; Podratz KC; Jiang SW
    Gynecol Oncol; 2005 Oct; 99(1):126-34. PubMed ID: 16023706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical clustering of gynecologic malignancies: A family study including molecular analysis of candidate genes.
    Cohn DE; Babb S; Whelan AJ; Mutch DG; Herzog TJ; Rader JS; Elbendary A; Goodfellow PJ
    Gynecol Oncol; 2000 Apr; 77(1):18-25. PubMed ID: 10739686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging issues of the expression profiling technologies for the study of gynecologic cancer.
    Pappa KI; Anagnou NP
    Am J Obstet Gynecol; 2005 Sep; 193(3 Pt 2):908-18. PubMed ID: 16157086
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonality in gynecologic neoplasms: is it time to reevaluate clonality studies in gynecologic neoplasms? Is it possible to confirm multicentricity with clonality studies?
    Silva EG; Matias-Guiu X
    Ann Diagn Pathol; 2012 Aug; 16(4):312-4. PubMed ID: 22417864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The gynecologic oncology model: research.
    Chambers SK
    Surg Oncol Clin N Am; 1998 Apr; 7(2):255-62. PubMed ID: 9537974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene therapy in gynecological cancer.
    Brooks RA; Mutch DG
    Expert Rev Anticancer Ther; 2006 Jul; 6(7):1013-32. PubMed ID: 16831074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microarray analysis of gene expression in gynecologic cancers--still only the beginning.
    Berchuck A
    Gynecol Oncol; 2009 Jul; 114(1):1-2. PubMed ID: 19497432
    [No Abstract]   [Full Text] [Related]  

  • 10. Genomic profiling of breast cancer.
    Pandey A; Singh AK; Maurya SK; Rai R; Tewari M; Kumar M; Shukla HS
    J Surg Oncol; 2009 May; 99(6):386-92. PubMed ID: 19235775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Present status in and future prospects for development of protein function inhibitors for gynecologic neoplasms].
    Wake N
    Fukuoka Igaku Zasshi; 2006 Nov; 97(11):311-4. PubMed ID: 17228784
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetic aspects of (gynecological) tumours.
    Oosterwijk JC
    Eur J Obstet Gynecol Reprod Biol; 1999 Feb; 82(2):125-8. PubMed ID: 10206401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of CRASH, a gene deregulated in gynecological tumors.
    Evtimova V; Zeillinger R; Kaul S; Weidle UH
    Int J Oncol; 2004 Jan; 24(1):33-41. PubMed ID: 14654938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Screening for gynecologic malignancies: A continuing responsibility.
    Runowicz CD; Fields AL
    Surg Oncol Clin N Am; 1999 Oct; 8(4):703-23, vii. PubMed ID: 10452936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Oncogenes in gynecological malignancies].
    Zhang X
    Zhonghua Fu Chan Ke Za Zhi; 1995 Nov; 30(11):643-6. PubMed ID: 8745485
    [No Abstract]   [Full Text] [Related]  

  • 16. [Basic research and applying molecular genetics: not a correction of creation].
    Nellen W
    Pflege Z; 2005 Nov; 58(11):677-9. PubMed ID: 16329690
    [No Abstract]   [Full Text] [Related]  

  • 17. Mutations and altered expression of the human cancer genes: what they tell us about causes.
    Devereux TR; Risinger JI; Barrett JC
    IARC Sci Publ; 1999; (146):19-42. PubMed ID: 10353382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Problems in association with basic research and biologic therapy of gynecologic malignancies].
    Kong BH
    Zhonghua Fu Chan Ke Za Zhi; 2003 Aug; 38(8):493-6. PubMed ID: 14627039
    [No Abstract]   [Full Text] [Related]  

  • 19. [The tumor-associated antigen CA-125 under normal and in pathologic conditions].
    Ermoshina NV; Sergeeva NS; Akhmedova SA; Mishunina MP; Novikova EG
    Vopr Onkol; 2000; 46(5):529-37. PubMed ID: 11202183
    [No Abstract]   [Full Text] [Related]  

  • 20. Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
    Bakkum-Gamez JN; Aletti G; Lewis KA; Keeney GL; Thomas BM; Navarro-Teulon I; Cliby WA
    Gynecol Oncol; 2008 Jan; 108(1):141-8. PubMed ID: 17988723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.